PDSB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PDS Biotechnology Corp (PDSB) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is currently in a bearish technical trend, has weak financial performance, and lacks positive catalysts or strong trading signals. The pre-market price is also down significantly (-4.56%), and there are no signs of institutional or insider buying to support confidence in the stock.
The technical indicators suggest a bearish trend. The MACD is positive but contracting, RSI is neutral at 41.193, and moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 0.62), but there is no clear indication of a reversal.
NULL. There are no recent news updates, no significant insider or hedge fund activity, and no recent congress trading data. Additionally, there are no upcoming events or earnings reports that could act as a catalyst in the short term.
is also down -1.38%. Financial performance is weak, with declining net income (-16.01% YoY) and EPS (-34.48% YoY). The lack of institutional or insider buying further weakens confidence.
In Q3 2025, PDSB reported no revenue growth (0% YoY), a net income loss of -$9,009,411 (-16.01% YoY), and a significant drop in EPS to -0.19 (-34.48% YoY). Gross margin remains at 0%. The financials indicate poor performance with no signs of improvement.
No data available on analyst ratings or price target changes. This lack of coverage may indicate limited interest or confidence in the stock.
